BridgeBio
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 8.2m | 69.7m | 77.6m | 9.3m | 385m | 237m | 552m |
| % growth | (80 %) | 745 % | 11 % | (88 %) | 4034 % | (38 %) | 133 % |
| EBITDA | (469m) | (540m) | (354m) | (575m) | (33.4m) | (520m) | (253m) |
| % EBITDA margin | (5684 %) | (774 %) | (455 %) | (6177 %) | (9 %) | (219 %) | (46 %) |
| Profit | (449m) | (563m) | (481m) | (643m) | (404m) | (582m) | (385m) |
| % profit margin | (5440 %) | (807 %) | (620 %) | (6914 %) | (105 %) | (246 %) | (70 %) |
| EV / revenue | 1071.3x | 47.6x | 31.8x | 893.8x | 16.5x | 27.9x | 12.3x |
| EV / EBITDA | -18.9x | -6.2x | -7.0x | -14.5x | -189.8x | -12.7x | -26.8x |
| R&D budget | 337m | 454m | 403m | 456m | - | - | - |
| R&D % of revenue | 4086 % | 651 % | 519 % | 4899 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | $299m | Growth Equity VC | |
| N/A | N/A | IPO | |
| N/A | $475m | Post IPO Debt | |
* | N/A | $250m | Post IPO Debt |
* | N/A | $750m | Post IPO Debt |
* | N/A | $150m | Post IPO Equity |
* | $250m | Private Placement VC | |
* | N/A | Post IPO Debt | |
* | N/A | $250m | Post IPO Equity |
* | $200m | Post IPO Equity | |
| Total Funding | AUD1.1b | ||
Related Content
Recent News about BridgeBio
EditBridgeBio Pharma, headquartered in Palo Alto, California, is a biotechnology company focused on developing medicines for genetic diseases. The company operates in the biopharmaceutical market, targeting conditions where the underlying genetic cause is well understood. BridgeBio's business model is unique in that it employs a decentralized subsidiary approach. This means that while the company provides shared central resources, each subsidiary remains focused on developing therapies for specific diseases. This structure allows for efficiency and speed, enabling the company to advance multiple drug programs simultaneously.
BridgeBio serves a diverse range of clients, primarily including patients suffering from genetic diseases, healthcare providers, and medical researchers. The company leverages breakthroughs in genome sequencing, molecular biology, and patient information databases to identify promising scientific research and translate it into effective treatments. By focusing on diseases at their genetic source, BridgeBio aims to create therapies that can make significant therapeutic leaps.
The company makes money through the development and commercialization of its drug programs. This includes licensing agreements, partnerships with other pharmaceutical companies, and eventually, the sale of approved therapies. BridgeBio's pipeline is robust, with more than 15 drug programs targeting 20 different genetic diseases. This diversified approach reduces the traditional biopharma process timeline, potentially bringing treatments to market faster.
BridgeBio's commitment to independent thinking and radical transparency fosters a culture where innovative ideas are rigorously tested and adopted if proven effective. This mindset, combined with their decentralized model, allows for quick, data-driven decision-making across multiple programs, enhancing both speed and scale.
Keywords: biotechnology, genetic diseases, decentralized model, drug development, genome sequencing, molecular biology, patient databases, therapeutic leaps, commercialization, innovative therapies.
